08:37 AM EDT, 09/02/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Tuesday that a substudy evaluating its Varipulse platform for pulsed field ablation procedures for atrial fibrillation demonstrated a strong safety profile, a 99.7% acute effectiveness, and procedural efficiency among 791 patients. The company said that the Varipulse platform, which consists of the Varipulse catheter and Trupulse...

08:35 AM EDT, 09/02/2025 (MT Newswires) -- Zenas BioPharma ( ZBIO ) and Royalty Pharma ( RPRX ) said Tuesday that the latter will offer up to $300 million in financing in exchange for a royalty on sales of monoclonal antibody obexelimab. Obexelimab is in phase 3 development to treat immunoglobulin G4-related disease (IgG4-RD), and phase 2 development for relapsing...

08:39 AM EDT, 09/02/2025 (MT Newswires) -- Eastern Bankshares ( EBC ) was Smart Insider's stock pick of the week after the company's Chief Executive Denis Sheahan purchased $497,000 worth of company shares at $16.71 apiece on Aug. 25, raising his ownership by 12%. Chairman Robert Rivers also bought $745,968 worth of the bank's shares at $16.71 apiece on the...

08:33 AM EDT, 09/02/2025 (MT Newswires) -- Editas Medicine ( EDIT ) said Tuesday it has nominated EDIT-401, an LDLR-targeted therapy for hyperlipidemia, as its lead in vivo development candidate. The experimental treatment reduced LDL cholesterol by nearly 90% with a single dose in non-human primates, the company said. EDIT-401 is designed as a one-time gene editing therapy to increase...